CARDURA® XL [Prescribing Information]. New York City,
NY: Pfizer Inc; 2006.
Chung M, Vashi V, Puente J, Sweeney M, Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.
Br J Clin Pharmacol. 1999;48:678-687.
Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Høye K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system,
doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU
Int. 2001;87:192-200.
Andersen M, Dahlstrand C, Hye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur
Urol. 2000;38:400-409.
McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
N Engl J Med. 2003;349:2387-2398.
CARDURA XL is contraindicated in patients
with a known sensitivity to other quinazolines (eg, prazosin,
terazosin), doxazosin, or any of the inert ingredients. Postural
hypotension with or without symptoms (eg, dizziness) may
develop within a few hours following administration of CARDURA
XL. However, infrequently, symptomatic postural hypotension
has also been reported later than a few hours after dosing.
Caution should be used when administering CARDURA XL to patients
with preexisting severe gastrointestinal tract narrowing,
chronic constipation, or evidence of hepatic dysfunction.
The most commonly reported adverse events were: headache, dizziness, respiratory tract infection, asthenia, and back pain.
